Back

Reduction in total cardiovascular events with evolocumab in patients with no prior myocardial infarction or stroke: a pre-specified analysis of VESALIUS-CV

29 August 2026 (15:10 - 15:20)
Organised by: Logo
Congress Presentation Part of: Lipid lowering in the prevention era: from statins to RNA therapeutics Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Jose Carlos Nicolau

Heart Institute of the University of Sao Paulo (InCor), Sao Paulo (Brazil)

4 More presentations in this session

Presentation thumbnail
The clinical benefits of immediate versus delayed use of PCSK9 inhibitors for patients with established atherosclerotic cardiovascular disease in the UK
Professor K. Ray (London, GB)
Abstract Slides Video
Presentation thumbnail
Alirocumab and cardiovascular outcomes in patients without a prior ischemic event
Assistant Professor M. Leening (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Potent and sustained blood pressure reduction with a novel small interfering RNA targeting hepatic angiotensinogen: results from a first-in-human, randomised, phase 1 study
Doctor M. Yang (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Association of cancer incidence and cancer mortality with statins, ezetimibe, and statin–ezetimibe therapy: a pairwise and bayesian network meta-analysis of randomized controlled trials
Doctor S. Saluja (New Delhi, IN)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid lowering in the prevention era: from statins to RNA therapeutics
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 15:10 CET
You may be interested in
thumbnail
Congress Presentation
Evolocumab and risk of a first myocardial infarction: a prespecified analysis of the VESALIUS-CV trial
28 August 2026
thumbnail
Congress Presentation
Lower rate of ischemic events with PCSK9 inhibition in patients with atherosclerotic cardiovascular disease but without prior ischemic events
30 August 2024
thumbnail
Congress Presentation
Three decades of secondary prevention in ASCVD: temporal trends in risk factors and recurrent cardiovascular events
28 August 2026
thumbnail
Congress Presentation
Lipoprotein(a), smoking, and diabetes are additive, but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome: An analysis of the ODYSSEY OUTCOMES trial
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources